Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ELDN
SellEledon Pharmaceuticals, Inc. · Healthcare · United States · $277M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing novel immunology therapies for patients with autoimmune diseases and organ transplant recipients. The company's lead therapeutic candidate focuses on inhibiting the CD40L pathway, aiming to prevent organ rejection and treat severe autoimmune conditions. It distinguishes itself by targeting critical immune checkpoints with the potential to offer safer and more effective treatment options for immune-mediated diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -1.10 | -1.17 | -0.66 | -0.52 | — | -0.90 | -0.93 | -0.77 | — |
| Shares | 77.2M | 77.2M | 59.8M | 75.4M | -2.3% | 81.3M | — | — | — |
| Debt | 0.7M | 0.4M | 1.0M | 0.6M | -4.9% | 0.5M | — | — | — |
| Equity | 84.2M | 7.2M | 62.4M | 81.1M | -1.2% | — | — | — | — |
| Op CF | -28.4M | -39.5M | -47.3M | -62.3M | — | -73.9M | — | — | — |
| Inv CF | 0 | -45.3M | -70.3M | 10.8M | — | — | — | — | — |
| Fin CF | 0 | 33.0M | 133.5M | 53.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ELDN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ELDN | Eledon Pharmaceuticals, Inc.(you) | $277M | 22 | Sell |
| ALXO | ALX Oncology Holdings Inc. | $275M | 21 | Sell |
| FATE | Fate Therapeutics, Inc. | $292M | 22 | Sell |
| FULC | Fulcrum Therapeutics, Inc. | $293M | 19 | Strong Sell |
| IMRX | Immuneering Corporation | $335M | 21 | Sell |
| VNDA | Vanda Pharmaceuticals Inc. | $322M | 20 | Sell |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $356M | 22 | Sell |
| RNAC | Cartesian Therapeutics, Inc. | $304M | 17 | Strong Sell |
| SION | Sionna Therapeutics, Inc. | $252M | 17 | Strong Sell |
| OBIO | Orchestra BioMed Holdings, Inc. | $327M | 18 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%